Clinical event rate in patients with and without left main disease undergoing isolated coronary artery bypass grafting: results from the European DuraGraft Registry.
Coronary artery bypass grafting
Endothelial damage inhibitor
Left main disease
Major adverse cardiac events
Journal
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069
Informations de publication
Date de publication:
02 09 2022
02 09 2022
Historique:
received:
18
02
2022
revised:
25
07
2022
accepted:
01
08
2022
pubmed:
6
8
2022
medline:
28
9
2022
entrez:
5
8
2022
Statut:
ppublish
Résumé
Left main coronary artery disease (LMCAD) is considered an independent risk factor for clinical events after coronary artery bypass grafting (CABG). We have conducted a subgroup analysis of the multicentre European DuraGraft Registry to investigate clinical event rates at 1 year in patients with and without LMCAD undergoing isolated CABG in contemporary practice. Patients undergoing isolated CABG were selected. The primary end point was the incidence of a major adverse cardiac event (MACE) defined as the composite of death, myocardial infarction (MI) or repeat revascularization (RR) at 1 year. The secondary end point was major adverse cardiac and cerebrovascular events (MACCE) defined as MACE plus stroke. Propensity score matching was performed to balance for differences in baseline characteristics. LMCAD was present in 1033 (41.2%) and absent in 1477 (58.8%) patients. At 1 year, the MACE rate was higher for LMCAD patients (8.2% vs 5.1%, P = 0.002) driven by higher rates of death (5.4% vs 3.4%, P = 0.016), MI (3.0% vs 1.3%, P = 0.002) and numerically higher rates of RR (2.8% vs 1.8%, P = 0.13). The incidence of MACCE was 8.8% vs 6.6%, P = 0.043, with a stroke rate of 1.0% and 2.4%, P = 0.011, for the LMCAD and non-LMCAD groups, respectively. After propensity score matching, the MACE rate was 8.0% vs 5.2%, P = 0.015. The incidence of death was 5.1% vs 3.7%, P = 0.10, MI 3.0% vs 1.4%, P = 0.020, and RR was 2.7% vs 1.6%, P = 0.090, for the LMCAD and non-LMCAD groups, respectively. Less strokes occurred in LMCAD patients (1.0% vs 2.4%, P = 0.017). The MACCE rate was not different, 8.5% vs 6.7%, P = 0.12. In this large registry, LMCAD was demonstrated to be an independent risk factor for MACE after isolated CABG. Conversely, the risk of stroke was lower in LMCAD patients. ClinicalTrials.gov NCT02922088.
Identifiants
pubmed: 35929787
pii: 6656349
doi: 10.1093/ejcts/ezac403
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02922088']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Katharina Huenges
(K)
Herko Grubitzsch
(H)
Farhad Bakthiary
(F)
Jörg Kempfert
(J)
Adam J Penkalla
(AJ)
Bernhard C Danner
(BC)
Fawad A Jebran
(FA)
Carina Benstoem
(C)
Andreas Goetzenich
(A)
Christian Stoppe
(C)
Elmar W Kuhn
(EW)
Oliver J Liakopoulos
(OJ)
Stefan Brose
(S)
Klaus Matschke
(K)
Dave Veerasingam
(D)
Kishore Doddakula
(K)
Lorenzo Guerrieri Wolf
(LG)
Giuseppe Filiberto Serraino
(GF)
Pasquale Mastroroberto
(P)
Nicola Lamascese
(N)
Massimo Sella
(M)
Edmundo R Fajardo-Rodriguez
(ER)
Alejandro Crespo
(A)
Angel L Fernandez Gonález
(ALF)
Alvaro Pedraz
(A)
Elena Arnáiz-García
(E)
Ignacio Muñoz Carvajal
(IM)
Adrian J Fontaine
(AJ)
José Ramón González Rodríguez
(JRG)
José Antonio Corrales Mera
(JAC)
Paloma Martinez
(P)
Jose Antonio Blazquez
(JA)
Bella Ramirez
(B)
Alejandro Adsuar-Gomez
(A)
Jose M Borrego-Dominguez
(JM)
Christian Muñoz-Guijosa
(C)
Sara Badía-Gamarra
(S)
Rafael Sádaba
(R)
Alicia Gainza
(A)
Manuel Castellá
(M)
Gregorio Laguna
(G)
Javier A Gualis
(JA)
Stefanos Demertzis
(S)
Jürg Grünenfelder
(J)
Robert Bauernschmitt
(R)
Amal K Bose
(AK)
Nawwar Al-Attar
(N)
George Gradinariu
(G)
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.